The basis for my optimism is that we're seeing the issues of scale-up being worked out with the mRNA vaccine supplies that we have purchased. We have also purchased other vaccines, notably two that are adenovirus based: AstraZeneca and Johnson & Johnson, whose results are excellent and, as has been mentioned, have been approved in other countries, at least in the case of AstraZeneca. Johnson & Johnson is being studied both in Canada and the U.S. for approval. Adenovirus is a much easier production and easier to scale up. We shouldn't expect a lot of hiccups there. There will be additional doses. Last but not least is the Novavax, which is the protein subunit that has also shown great results. The production should be easier.
We should be getting three additional vaccines in the coming months for Canada. Already, based only on the RNA vaccines, we have enough doses to vaccinate people who want to be vaccinated by September. That's the basis of my optimism.
I do have to mention, though, that we do need to have logistics in place to achieve all this.